

Cardiology Associates, Inc.

Masahiro Mori, MD
William M. Dang, Jr, MD
A. Jim Terakubo, MD
Gregory A. Cogert, MD

FAX Notice

Date:	09/12/07
To:	Roberto J. Torres, Senior Health Physicist U.S. Nuclear Regulatory Commission, Region IV
Fax Number:	817 860 8188
From:	Pat Poe
Subject:	License Amentment Request for RAML number 53-29211-01 Expedited Request to Add Authorized User 030-37007
Number of Pages Transmitted (including cover page)	18 pages

This communication is intended solely for the individual or the entity to which it is addressed, and may contain information that is privileged, confidential and/or prohibited from disclosure. If the reader of this communication is not the intended recipient, you are hereby notified that any review, dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone. Thank you.

9/17/07
Applicant meets 10 CFR 35.13(b)(1) exception under
10 CFR 35.290(a) → Board certification pathway. Name
Dr. Cogert as 35.200 AU.

RITC 9/17/07

Main Office 1329 Lusitana Street, Suite 409; Honolulu, Hawaii 96813, Phone (808) 521-8211 Fax (808) 523-5973
Branch Offices Pali Momi Medical Center Wahiawa General Hospital Physicians Exchange (808) 524-2575

4 7 1 5 0 2

Cardiology Associates, Inc.

Masahiro Mori, MD
William M. Dang, Jr, MD
A. Jim Terakubo, MD
Gregory A. Cogert, MD

Security-Related Information
Withhold Under 10 CFR 2.390

September 12, 2007

Roberto J. Torres
Senior Health Physicist
U.S. Nuclear Regulatory Commission, Region IV
Division of Nuclear Materials Safety
Nuclear Materials Licensing Branch
611 Ryan Plaza Drive, Suite 400
Arlington, Texas, 76011

Re: License Amendment Request for RAML Number 53-29211-01
Expedited Request to Add Authorized User


Dear Mr. Torres:

Cardiology Associates Incorporated is submitting an expedited amendment request to add an Authorized User onto our radioactive materials license for Gregory A. Cogert, MD who started on July 9th, 2007.

Enclosed with this letter is NRC FORM 313A (AUD), the Preceptor Attestation signed by Dr. Daniel S. Berman at Cedars-Sinai Medical Center, and his Certificate from the Certification Board of Nuclear Cardiology. Also enclosed is a copy of his Physician license with the State of Hawaii and his most recent resume.

Thank you for your expedited review of this license amendment, and please do not hesitate to give our Finance Manager, Pat Poe a call at 808 521-8211 ext 102 or email pat@cardiohawaii.com if you have any further questions or concerns.

Sincerely,



William M. Dang, Jr., MD
President

cc Blaine Ikeda, PharmD
Radiation Safety Officer

Enclosures

NRC FORM 313A (AUD) (3-2007)		U.S. NUCLEAR REGULATORY COMMISSION		APPROVED BY OMB: NO. 3150-0120 EXPIRES: 10/31/2008	
AUTHORIZED USER TRAINING AND EXPERIENCE AND PRECEPTOR ATTESTATION (for uses defined under 35.100, 35.200, and 35.500) [10 CFR 35.190, 35.290, and 35.590]					
Name of Proposed Authorized User Gregory Cogert, MD			State or Territory Where Licensed Hawaii		
Requested Authorization(s) (check all that apply)					
<input type="checkbox"/> 35.100 Uptake, dilution, and excretion studies					
<input checked="" type="checkbox"/> 35.200 Imaging and localization studies					
<input type="checkbox"/> 35.500 Sealed sources for diagnosis (specify device _____)					
PART I -- TRAINING AND EXPERIENCE (Select one of the three methods below)					
* Training and Experience, including board certification, must have been obtained within the 7 years preceding the date of application or the individual must have obtained related continuing education and experience since the required training and experience was completed. Provide dates, duration, and description of continuing education and experience related to the uses checked above.					
<input checked="" type="checkbox"/> 1. Board Certification					
a. Provide a copy of the board certification.					
b. If using only 35.500 materials, stop here. If using 35.100 and 35.200 materials, skip to and complete Part II Preceptor Attestation.					
<input type="checkbox"/> 2. Current 35.390 Authorized User Seeking Additional 35.290 Authorization					
a. Authorized user on Materials License _____ meeting 10 CFR 35.390 or equivalent Agreement State requirements seeking authorization for 35.290.					
b. Supervised Work Experience. (If more than one supervising individual is necessary to document supervised work experience, provide multiple copies of this section.)					
Description of Experience		Location of Experience/License or Permit Number of Facility		Clock Hours	Dates of Experience*
Eluting generator systems appropriate for the preparation of radioactive drugs for imaging and localization studies, measuring and testing the eluate for radionuclidic purity, and processing the eluate with reagent kits to prepare labeled radioactive drugs					
Total Hours of Experience:					
Supervising Individual			License/Permit Number listing supervising individual as an authorized user		
Supervisor meets the requirements below, or equivalent Agreement State requirements (check all that apply).					
<input type="checkbox"/> 35.290 <input type="checkbox"/> 35.390 + generator experience in 32.290(c)(1)(ii)(G)					

NRC FORM 313A (AUD)

U.S. NUCLEAR REGULATORY COMMISSION

(3-2007)

AUTHORIZED USER TRAINING AND EXPERIENCE AND PRECEPTOR ATTESTATION (continued)

☐ 3. Training and Experience for Proposed Authorized User

a. Classroom and Laboratory Training.

Description of Training	Location of Training	Clock Hours	Dates of Training*
Radiation physics and instrumentation			
Radiation protection			
Mathematics pertaining to the use and measurement of radioactivity			
Chemistry of byproduct material for medical use (<i>not required for 35.590</i>)			
Radiation biology			
Total Hours of Training:			

- b. Supervised Work Experience (completion of this table is not required for 35.590).
(If more than one supervising individual is necessary to document supervised work experience, provide multiple copies of this section.)

Supervised Work Experience		Total Hours of Experience:	
Description of Experience Must Include:	Location of Experience/License or Permit Number of Facility	Confirm	Dates of Experience*
Ordering, receiving, and unpacking radioactive materials safely and performing the related radiation surveys		<input type="checkbox"/> Yes <input type="checkbox"/> No	
Performing quality control procedures on instruments used to determine the activity of dosages and performing checks for proper operation of survey meters		<input type="checkbox"/> Yes <input type="checkbox"/> No	

NRC FORM 313A (AUD)
(3-2007)

U.S. NUCLEAR REGULATORY COMMISSION

AUTHORIZED USER TRAINING AND EXPERIENCE AND PRECEPTOR ATTESTATION (continued)

3. Training and Experience for Proposed Authorized User (continued)

b. Supervised Work Experience. (continued)

Description of Experience Must Include:	Location of Experience/License or Permit Number of Facility	Confirm	Dates of Experience*
Calculating, measuring, and safely preparing patient or human research subject dosages		<input type="checkbox"/> Yes <input type="checkbox"/> No	
Using administrative controls to prevent a medical event involving the use of unsealed byproduct material		<input type="checkbox"/> Yes <input type="checkbox"/> No	
Using procedures to contain spilled byproduct material safely and using proper decontamination procedures		<input type="checkbox"/> Yes <input type="checkbox"/> No	
Administering dosages of radioactive drugs to patients or human research subjects		<input type="checkbox"/> Yes <input type="checkbox"/> No	
Eluting generator systems appropriate for the preparation of radioactive drugs for imaging and localization studies, measuring and testing the eluate for radionuclidic purity, and processing the eluate with reagent kits to prepare labeled radioactive drugs		<input type="checkbox"/> Yes <input type="checkbox"/> No	

Supervising Individual

License/Permit Number listing supervising individual as an authorized user

Supervisor meets the requirements below, or equivalent Agreement State requirements (check one).

☐ 35.190 ☐ 35.290 ☐ 35.390 ☐ 35.390 + generator experience in 35.290(c)(1)(ii)(G)

c. For 35.590 only, provide documentation of training on use of the device.

Device	Type of Training	Location and Dates

d. For 35.500 uses only, stop here. For 35.100 and 35.200 uses, skip to and complete Part II Preceptor Attestation.

NRC FORM 313A (AUD)

U.S. NUCLEAR REGULATORY COMMISSION

(9-2007)

AUTHORIZED USER TRAINING AND EXPERIENCE AND PRECEPTOR ATTESTATION (continued)

PART II -- PRECEPTOR ATTESTATION

Note: This part must be completed by the individual's preceptor. The preceptor does not have to be the supervising individual as long as the preceptor provides, directs, or verifies training and experience required. If more than one preceptor is necessary to document experience, obtain a separate preceptor statement from each. (Not required to meet training requirements in 35.590)

First Section

Check one of the following for each use requested:

For 35.190

Board Certification

☐ I attest that _____ has satisfactorily completed the requirements in
Name of Proposed Authorized User

10 CFR 35.190(a)(1) and has achieved a level of competency sufficient to function independently as an authorized user for the medical uses authorized under 10 CFR 35.100.

OR

Training and Experience

☐ I attest that _____ has satisfactorily completed the 60 hours of training and
Name of Proposed Authorized User

experience, including a minimum of 8 hours of classroom and laboratory training, required by 10 CFR 35.190(c)(1), and has achieved a level of competency sufficient to function independently as an authorized user for the medical uses authorized under 10 CFR 35.100.

For 35.290

Board Certification

☐ I attest that _____ has satisfactorily completed the requirements in
Name of Proposed Authorized User

10 CFR 35.290(a)(1) and has achieved a level of competency sufficient to function independently as an authorized user for the medical uses authorized under 10 CFR 35.100 and 35.200.

OR

Training and Experience

☐ I attest that _____ has satisfactorily completed the 700 hours of training
Name of Proposed Authorized User

and experience, including a minimum of 80 hours of classroom and laboratory training, required by 10 CFR 35.290(c)(1), and has achieved a level of competency sufficient to function independently as an authorized user for the medical uses authorized under 10 CFR 35.100 and 35.200.

Second Section

Complete the following for preceptor attestation and signature:

☐ I meet the requirements below, or equivalent Agreement State requirements, as an authorized user for:

☐ 35.190 ☐ 35.290 ☐ 35.390 ☐ 35.390 + generator experience

Name of Preceptor

Daniel S. Berman, MD, FACC

Signature

See attached letter

Telephone Number

Date

License/Permit Number/Facility Name



CEDARS-SINAI MEDICAL CENTER.

May 23, 2006

Certification Board of Nuclear Cardiology
19562 Club House Road
Montgomery Village, MD 20886

RE: Gregory Cogert, MD

To Whom It May Concern:

Dr. Gregory Cogert has completed a fellowship training program in nuclear cardiology that meets the requirements as outlined in the ACC/A5NC COCATS Guidelines [revised 2000].

Dr. Gregory Cogert is competent to independently function as an authorized user under NRC 10 CFR 35.290 uscs.

Sincerely,

Daniel S. Berman, MD, FACC
Director, Cardiac Imaging
Professor, UCLA-David Geffen School of Medicine

Agreement State Authorized User Number: 0404-19

Certification Board of Nuclear Cardiology

Incorporated 1996

Certifies That

Gregory Alexander Cogert, MD

HAVING MET THE REQUIREMENTS PRESCRIBED BY THIS BOARD
FOR PHYSICIANS TRAINED IN THE UNITED STATES
AND HAVING SATISFACTORILY PASSED THE REQUIRED EXAMINATION,
IS HEREBY DESIGNATED

A DIPLOMATE CERTIFIED IN THE SUBSPECIALTY OF

NUCLEAR CARDIOLOGY

FOR THE PERIOD 2006-2016

M. J. Venzel


Secretary



CERTIFICATE NUMBER 4703

[Signature]

President



SEP-12-2007 WED 01:46 PM CARDIOLOGY ASSOC INC

FAX NO. 5235973

P. 09

SEP-07-2007 FRI 06:29 AM CARDIOLOGY ASSOC INC

FAX NO. 5235973

P. 02/11

LICENSE NUMBER
MD - 14170

EXPIRATION DATE
01/31/2008

STATE OF HAWAII DEPARTMENT OF COMMERCE AND CONSUMER AFFAIRS
PHYSICIAN

GREGORY A COGERT

(SIGNATURE
OF LICENSEE)



GREGORY ALEXANDER COGERT**PERSONAL**

Home Address

Phone

E-mail

EDUCATION & APPOINTMENTS

Fellowship in Cardiovascular Medicine Cedars-Sinai Medical Center, Los Angeles, CA	2004-2007
Residency in Internal Medicine UCLA Medical Center, Los Angeles, CA	2002 - 2004
Internship in Internal Medicine UCLA Medical Center, Los Angeles, CA	2001 - 2002
College of Medicine University of California, Irvine (MD)	1997 - 2001
Microbiology and Molecular Genetics University of California, Los Angeles (BS)	1993 - 1997

CERTIFICATIONS

National Board of Echocardiography (NBE); Certification Pending Passed Examination of Special Competence in Adult (ASCeXAM)	2007
Certification board of Nuclear Cardiology (CNBC)	2006
Advanced Cardiac Life Support (ACLS) American Heart Association	2006
Cardiopulmonary Resuscitation and Emergency Cardiac Care (BLS) American Heart Association	2006
American Board of Internal Medicine (ABIM)	2004

EMPLOYMENT

General Cardiologist 2007-present
Cardiology Associates Inc.
1329 Lusitana Ave, suite 409
Honolulu, HI 96813

Heart Transplant Data Analyst 1994 - 1998
University of California, Los Angeles
Department of Medicine, Division of Cardiology,
Cardiac Transplant Program

HONORS & AWARDS

Alpha Omega Alpha Honor Medical Society 2000

Excellence in Research Award 1999
American Federation for Medical Research, Western Regional Meeting

Excellence in Research Award 1997
American Federation for Medical Research, Western Regional Meeting

Trainee Investigators Award for Excellence in Scientific Research 1996
American Federation for Clinical Research, National Meeting

Excellence in Research Award 1996
American Federation for Clinical Research, Western Regional Meeting

RESEARCH EXPERIENCE

Cedars-Sinai Department of Electrophysiology 2006-2007

- Peng-Sheng Chen, MD, Director of Electrophysiology Research
- Reviewing catheter based ablation strategies for atrial fibrillation
- Investigating the potential of gated nuclear perfusion imaging as an alternative to tissue Doppler echocardiography to evaluate electro-mechanical dyssynchrony and identify responders to cardiac resynchronization therapy.

Cedars-Sinai Department of Interventional Cardiology 2005-2006

- Neal Eigler, MD, Director Cardiovascular Intervention Center
- Research and development of new interventional procedures and devices, such as drug-eluting stents and implantable heart failure management systems.

- Developed porcine acute myocardial infarction model to evaluate the efficacy of an insulin eluting stent.

UCLA Cardiac Transplant Program

1994-2005

- Jon A Kobashigawa MD, Medical Director Cardiac Transplant Program.
- Assist with multi-institutional and UCLA clinical research projects.
- Supervised the construction and maintenance of UCLA's cardiac transplant database.

UCI Department of Cardiothoracic Surgery

1998-1999

- Jeffrey C Milliken MD, Chair Division of Cardiothoracic Surgery.
- Development of extended cardiac preservation and organ transport system
- Rabbit heart model with PEG-hemoglobin blood product for continuous perfusion preservation.

UCLA Department of Cardiothoracic Surgery

1995

- Hillel Laks MD, Chair Division of Cardiothoracic Surgery.
- Analyzed perioperative surgical procedures to optimize the viability of a non-beating heart donor
- Piglet heart model with cardiac reperfusion after ischemic arrest.

PUBLICATIONS

Manuscripts

1. Jon A Kobashigawa MD, Steven Katznelson MD, Hillel Laks MD, Jay A Johnson MD, Xiu Ming Wang MD, David Chia PhD, Paul Terasaki PhD, Alejandro Sabad BA, **Gregory A Cogert**, et al. Effect of Pravastatin on Outcome After Cardiac Transplantation. *N Eng J Med* 1995;333:621-627.
2. Jon A Kobashigawa, Alejandro Sabad, Davis Drinkwater, **Gregory Cogert**, Jaime D Moriguchi, Nobuyuki Kawata, Michelle A Hamilton, Antoine Hage, Hillel Laks. Pretransplant Panel Reactive Antibody Screens: Are They Truly a Marker For Poor Outcome After Cardiac Transplantation? *Circulation* 1996;94:294-297.
3. DL Serna, LL Powell, WC Wallace, J West, C Kahwaji, **GA Cogert**, P Smulowitz, E Steward, R Purdy, JC Milliken. Cardiac Function After 8-Hour Storage Using PEG-Hemoglobin vs. Crystalloid Perfusion. *ASAIO Journal* 2000 Sep-Oct;46(5):547-52.
4. Subherwal S, Kobashigawa JA, **Cogert G**, Patel J, Espejo M, Oeser B. Incidence of acute cellular rejection and non-cellular rejection in cardiac transplantation. *Transplant Proc.* 2004 Dec;36(10):3171-2.

5. Kobashigawa JA, Moriguchi JD, Laks H, Wenor L, Hage A, Hamilton MA, Cogert G, et al. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. *J Heart Lung Transplant.* 2005 Nov;24(11):1736-40.
6. Cogert G, Siegel RJ. Giant Floating Aortic Thrombus: A Rare Finding on Transesophageal Echocardiography. *Am J Cardiol. In Press* 2007 Mar.
7. Cogert G, Chen PS. Pseudo T Wave Alternans. *J Cardiovasc Electrophysiol.* 2007 Jun; 18(6):679.

Scientific Abstracts

1. JA Kobashigawa, H Laks, A Sabad, G Cogert, et al. Long Term Experience with Mono-Immunosuppression in Select Cardiac Transplant Recipients. *J Heart Lung Transplant* 1995;14:244.
2. A Sabad, JA Kobashigawa, R Minkley, J Salamandra, S Ruzevich, J Chait, C Utley, G Cogert, et al. Is Pre-Operative Obesity a Relative Contraindication to Heart Transplantation? The Controversy Revisited. *J Heart Lung Transplant* 1995;14:155.
3. A Sabad, GA Cogert, JA Kobashigawa, et al. Use of an Inexpensive Structured Query Language Relational Database for Patient Management and Research. *J Investigative Medicine* April 1995;Vol 43;Supl. II:347A.
4. JA Kobashigawa, J Johnson, K Trosian, L Yeatman, A Sabad, GA Cogert, JD Moriguchi, et al. Cellular Rejection Does Not Appear To Be Associated With Intimal Thickening After One Year Post Cardiac Transplant: A Longitudinal Intravascular Ultrasound Study Using Quantitative Morphometric Analysis. *American Society of Transplant Physician*, May 1995:106.
5. JA Kobashigawa, A Sabad, GA Cogert, N Kawata, JD Moriguchi, MA Hamilton, AS Hage, DC Drinkwater, H Laks. Mild-Moderate Obesity After Cardiac Transplant Is Not Associated With Transplant Coronary Artery Disease Or Poor Outcome. *American Society of Transplant Physicians*, May 1995:142.
6. Jon Kobashigawa, Alejandro Sabad, Gregory Cogert, Jaime Moriguchi, et al. Preoperative Panel Reactive Antibody Screens: Are They Truly a Marker For Poor Outcome After Cardiac Transplantation? *Circulation* 1995;92:1-125.
7. Cheryl Westlake, Julie A Walden, Roxella Minkley, Gregg Fonarow, Michelle A Hamilton, Alejandro Sabad, Gregory Cogert, Jon A. Kobashigawa. Smoking and Abnormal Pulmonary Function Tests: Are They Risk Factors for Poor Outcome After Cardiac Transplantation? The Controversy Revisited. *Circulation* 1995;92:1-178.

8. Alejandro Sabad, Jon A Kobashigawa, **Gregory A Cogert**, Nobuyuki Kawata, et al. Is There Decreased Immunoresponsiveness In The Older Heart Transplant Recipient? A Case For Less Immunosuppression. UCLA International Symposium on Heart Failure & Heart Transplantation, November 1995.
9. A Sabad, M Hamilton, **G Cogert**, et al. Angiography as an Acceptable Risk in Cardiac Transplant Recipients With Borderline Renal Failure. *J Investigative Medicine*, January 1996;Vol 44(1);173A.
10. A Sabad, T Schneider, M Hamilton, **G Cogert**, et al. Estrogen Therapy as a Treatment for Hyperlipidemia in Female Heart Transplant Patients. *J Investigative Medicine* January 1996;Vol 44(1);173A.
11. **G Cogert**, M Hamilton, A Sabad, D Drinkwater, H Laks, and J Kobashigawa. Decreased Immune Response in Older Cardiac Transplant Recipients. *J Investigative Medicine* January 1996;Vol 44(1);157A.
12. A Sabad, **GA Cogert**, MA Hamilton, JA Kobashigawa. The Effects of Medical Insurance on Heart Transplant Outcome. *J of Investigative Medicine* March 1996;Vol 44(3);230A.
13. **GA Cogert**, A Sabad, MA Hamilton, JA Kobashigawa. Outcome of Heart Transplant Patients with Pre-Transplant Peripheral Vascular Disease. *J of Investigative Medicine* March 1996;Vol 44(3);246A.
14. J. Salamandra, J Kobashigawa, P Mansukhani, K Medkiff, S Ruzevich, R Minkley, J Chait, C Utley, A Wagner, A Sabad, **G Cogert**, D Drinkwater, H Laks. The Impact on Survival of Managed Care Transplant Patients Under The Care of Transplant Specialists. *American Society for Transplant Physicians*, May 1996.
15. J Kobashigawa, J Moriguchi, H Laks, M Hamilton, A Hage, N Kawata, A Sabad, **G Cogert**, H Muhlmeister, D Drinkwater. Successful Therapy for Cardiac Transplant Recipients with Hemodynamic Compromising Rejection. *Circulation* 1996;94(8):I-479.
16. J Kobashigawa, H Laks, G Fonarow, M Hamilton, J Moriguchi, A Hage, N Kawata, D Drinkwater, A Sabad, **G Cogert**, H Muhlmeister, G Schiller. Plasmapheresis for the Highly Sensitized Patient Before Heart Transplant. *Circulation* 1996;94(8):I-497.
17. J Kobashigawa, **G Cogert**, et al. Naturally Occurring Leukopenia as a Marker for Good Outcome After Cardiac Transplantation. *J Am Coll Cardiol* 1997;29(2A):28A.

18. J Kobashigawa, J Johnson, J Moriguchi, A Sabad, L Wener, G Cogert, et al. Obesity as a Risk Factor for Transplant Coronary Artery Disease: The IVUS Truth. *J Am Coll Cardiol* 1997;29(2A):291A.
19. GA Cogert, MA Hamilton, A Sabad, J Kobashigawa. Naturally Occurring Leukopenia After Cardiac Transplantation: A Marker for Tolerance? *J Investigative Medicine*, 1997.
20. HF Muhlmelster, MA Hamilton, GA Cogert, JD Cassen, A Sabad, J Kobashigawa. Long-Term HMG-CoA Reductase Inhibition Appears Safe and Effective After Cardiac Transplantation. *J Investigative Medicine*, 1997.
21. JA Kobashigawa, JD Moriguchi, A Sabad, E Albanese, GA Cogert, et al. Cyclosporine and Pravastatin Pharmacokinetics in Cardiac Transplant Recipients. *J Heart and Lung Transplant* 1997;16:84.
22. JD Moriguchi, JA Kobashigawa, A Sabad, MA Hamilton, A Hage, N Kawata, GA Cogert, et al. Estrogen Therapy in Post-Menopausal Heart Transplant Women May be Effective in Cholesterol Lowering. *J Heart and Lung Transplant* 1997;16:84.
23. JA Kobashigawa, J Czernin, H Laks, A Sabad, GA Cogert, et al. Pravastatin Preserves Coronary Endothelial-Dependent Vasodilation Determined by Positron Emission Tomography in Cardiac Transplant Patients. *J Heart and Lung Transplant* 1997;16:47.
24. J Johnson, JA Kobashigawa, LS Wener, C Stepanian, A Sabad, GA Cogert, et al. Histologic Validation of Morphometric Analysis of Intravascular Ultrasound in Quantitative Coronary Artery Disease. *J Heart and Lung Transplant* 1997;16:48.
25. JA Kobashigawa, TK Ro, K Einhorn, GA Cogert, et al. Risk Factors for Malignancies in Heart Transplant Recipients. *American Society for Transplant Physicians*, May 1998.
26. JA Kobashigawa, TK Ro, JD Moriguchi, JD Cassen, JA English, K Einhorn, GA Cogert, MA Hamilton, A Hage, N Kawata, H Laks. Cholesterol Lowering After Heart Transplantation is Associated with a Lower Incidence of Transplant Coronary Artery Disease. *American Society for Transplant Physicians*, 17th Annual Scientific Meeting, May 1998.
27. GA Cogert, JE West, DL Serna, JC Chen, JC Milliken. Pre-existing Renal Failure In Accelerated Recovery Pathway Patients After Cardiac Surgery. *J Investigative Medicine*, 1999; 47(2): 42A.

28. J West, WC Wallace, DL Serna, GA Cogert, JC Chen, JC Milliken. Outcome Analysis in patients returned to surgery for bleeding after coronary artery bypass surgery. *J Investigative Medicine*, 1999; 47(2): 42A.
29. MA Amster, GA Cogert, JE Scherger. Recommendation and Administration of Unconventional, Alternative, and Complementary Therapies by California Family Physicians. *J Investigative Medicine*, 1999; 47(2): 16A.
30. DL Serna, LL Powell, WC Wallace, J West, C Kahlwaji, G Cogert, P Smulowitz, E Steward, R Purdy, JC Milliken. Cardiac Function After 8-hour Storage Using PEG-Hemoglobin vs. Crystalloid Perfusion. *ASAIO* 1999; 45:142.
31. GA Cogert, JA Kobashigawa, ML Espejo, JD Moriguchi, J Patel, H Laks. Plasmapheresis Lowers the Incidence of Transplant Coronary Artery Disease Following Hemodynamic Compromising Heart Transplant Rejection. *American Society for Transplant Physicians*, 20th Annual Scientific Meeting, May 2001.
32. GA Cogert, S Subherwal, G Wu, et al. Incidence of Non Cellular (Humoral) Rejection Unchanged in the 1990's Decade Despite a Decrease in Cellular Rejection. *J Heart Lung Transplant* 2003.
33. GA Cogert, K Shivkumar, JK Patel et al. Implantable Cardioverter Defibrillators in Heart Transplant Patients at Risk for Sudden Death: Shocking News? *The J Heart Lung Transplant* 2003.
34. JA Kobashigawa, GA Cogert, JM Tobis, et. al. Improved Survival of Heart Transplant Patients with Severe Transplant Coronary Artery Disease in the Era of Percutaneous Coronary Artery Disease and Statin Therapy. *J Heart Lung Transplant* 2003.
35. JA Kobashigawa, Y Takano, JM Tobis, GA Cogert, et. al. Switch from Azathioprine to Mycophenolate Mofetil in Patients with Newly Diagnosed Angiographic Transplant Coronary Artery Disease: A Randomized Trial. *J Heart Lung Transplant* 2003.
36. BT cole, GA Cogert, ME Vassilakis et. al. The Effects of Medical Insurance on Heart Transplant Patient 10 Year Survival. *J Heart Lung Transplant* 2003.
37. S Subherwal, G Cogert, M Hamilton, et. al. Incidence of Non-cellular (Humoral) Rejection Unchanged in the 1990 Decade Despite a Decrease in Cellular Rejection. *J Investigative Medicine*, 2003.
38. SE Go, P Lee, NP Almeda, S Subherwal, G Cogert, et. al. The Effects of Immunosenscence on Biopsy Proven Rejection in Older Heart Transplant Recipients. *J Investigative Medicine*, 2003.

39. **GA Cogert, K Shivkumar, M Hamilton, et. al.** The Use of Implantable Cardioverter Defibrillators in Heart Transplant Patients at Risk for Sudden Death. *J Investigative Medicine*, 2003.
40. **JA Kobashigawa, GA Cogert, JM Tobis, et. al.** Improved Survival of Heart Transplant Patients with Severe Transplant Coronary Artery Disease in the Era of Percutaneous Coronary Intervention and Statin Therapy. *American Transplant Congress*, 2003.
41. **JA Kobashigawa, Y Takano, JM Tobis, GA Cogert, et. al.** A Randomized Trial Switching from Azathioprine to Mycophenolate Mofetil in Cardiac Transplant Patients with Newly Diagnosed Angiographic Transplant Coronary Artery Disease *American Transplant Congress*, 2003.
42. **JA Kobashigawa, G Cogert, JD Moriguchi, et. al.** The Highly Sensitized Patient Awaiting Heart Transplantation: Success with Combination Therapy of Plasmapheresis and Intravenous Gamma Globulin *The International Society for Heart and Lung Transplantation*, 24th Annual Meeting and Scientific Sessions, April 2004.
43. **JA Kobashigawa, JD Moriguchi, G Cogert, et. al.** 10-Year Results of the Pravastatin Randomized Trial in Heart Transplant Recipients. *The International Society for Heart and Lung Transplantation*, 24th Annual Meeting and Scientific Sessions, April 2004.
44. **SK Takemoto, G Cogert, BT Oeser et. al.** Outcome after pre-transplant plasmapheresis for sensitized recipients awaiting heart transplantation. *The International Society for Heart and Lung Transplantation*, 24th Annual Meeting and Scientific Sessions, April 2004.
45. **J Aragon, R Berg, S Kar, V Royter, G Cogert, et al.** Pimecrolimus Eluting Cobalt Stent Decreases Inflammation and Restenosis in a Porcine Model. *American Journal of Cardiology* 90(suppl 7a)23H, 2005.
46. **J Aragon, R Berg, S Kar, V Royter, G Cogert, et al.** A Pimecrolimus and Paclitaxel Dual Drug Eluting Stent: A synergistic response from drugs with different mechanism and different release kinetics from the COSTAR stent platform. *American Journal of Cardiology* 90(suppl 7a)8H, 2005.

PRESENTATIONS

1. **G Cogert, M Hamilton, A Sabad, D Drinkwater, H Laks, and J Kobashigawa.** Decreased Immune Response in Older Cardiac Transplant Recipients. *American Federation for Clinical Research, Western Regional Meeting*, February 1996.

Carmel, CA

2. **GA Cogert, A Sabad, MA Hamilton, JA Kobashigawa.** Outcome of Heart Transplant Patients with Pre-Transplant Peripheral Vascular Disease. American Federation for Clinical Research, National Meeting, Biomedicine, May 1996. Washington DC
3. **GA Cogert, MA Hamilton, A Sabad, J Kobashigawa.** Naturally Occurring Leukopenia After Cardiac Transplantation: A Marker for Tolerance? American Federation for Clinical Research, Western Regional Meeting, February 1997. Carmel, CA
4. **GA Cogert, JE West, DL Serna, JC Chen, JC Milliken.** Pre-existing Renal Failure in Accelerated Recovery Pathway Patients After Cardiac Surgery. American Federation for Clinical Research, Western Regional Meeting, February 1999. Carmel, CA
5. **GA Cogert, JA Kobashigawa, ML Espejo, JD Moriguchi, J Patel, H Laks.** Plasmapheresis Lowers the Incidence of Transplant Coronary Artery Disease Following Hemodynamic Compromising Heart Transplant Rejection. American Society for Transplant Physicians, 20th Annual Scientific Meeting, May 2001 Chicago, IL
6. **GA Cogert, K Shivkumar, M Hamilton, et. al.** The Use of Implantable Cardioverter Defibrillators in Heart Transplant Patients at Risk for Sudden Death. American Federation for Clinical Research, Western Regional Meeting, February 2003. Carmel, CA (substitute presenter)
7. **GA Cogert, S Subherwal, G Wu, et al.** Incidence of Non Cellular (Humoral) Rejection Unchanged in the 1990's Decade Despite a Decrease in Cellular Rejection. *The International Society for Heart and Lung Transplantation*, Annual Meeting and Scientific Sessions, April 2003 Vienna, Austria (substitute presenter)
8. **GA Cogert, K Shivkumar, JK Patel et al.** Implantable Cardioverter Defibrillators in Heart Transplant Patients at Risk for Sudden Death: Shocking News? *The International Society for Heart and Lung Transplantation*, Annual Meeting and Scientific Sessions, April 2003 Vienna, Austria (substitute presenter)